Alnylam Reports First Quarter 2017 Financial Results And Highlights Recent Period Activity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2017, and highlighted recent progress in advancing its pipeline.
“2017 promises to be a pivotal year for Alnylam. With our patisiran program, we look forward to the read-out of our APOLLO Phase 3 study and, if the data are positive, our first NDA filing. In addition, we expect to advance three additional programs into Phase 3 trials: fitusiran, givosiran, and – with our partners at The Medicines Company – inclisiran,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “In the first quarter and recent period, we made great progress with each of these programs, with positive clinical data reported from patisiran, fitusiran, and inclisiran, and achievement of PRIME designation for givosiran. As we look towards the rest of 2017, we believe our upcoming milestones put us on track to meet our ‘Alnylam 2020’ goals of becoming a multi-product, commercial-stage company with a deep and sustainable clinical development pipeline by the end of 2020.”
“2017 promises to be a pivotal year for Alnylam. With our patisiran program, we look forward to the read-out of our APOLLO Phase 3 study and, if the data are positive, our first NDA filing. In addition, we expect to advance three additional programs into Phase 3 trials: fitusiran, givosiran, and – with our partners at The Medicines Company – inclisiran,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “In the first quarter and recent period, we made great progress with each of these programs, with positive clinical data reported from patisiran, fitusiran, and inclisiran, and achievement of PRIME designation for givosiran. As we look towards the rest of 2017, we believe our upcoming milestones put us on track to meet our ‘Alnylam 2020’ goals of becoming a multi-product, commercial-stage company with a deep and sustainable clinical development pipeline by the end of 2020.”